[The study of renal safety in elderly patients with benign prostatic hyperplasia treated with α receptor blockers].

Objective: To investigate the renal safety in patients with benign prostatic hyperplasia treated with tamsulosin hydrochloride. Methods: A retrospective analysis of 10 cases of patients, who had renal dysfunction after treatment with long-term tamsulosin hydrochloride. Results: The average duration of oral medicine was 2 to 24 months with an average of 7.2 months. The serum creatinine after discontinuation of tamsulosin hydrochloride decreased from 132.5 µmol/L (100-208 µmol/L, normal 59-104 µmol/L) to 95.7 µmol/L (73-122 µmol/L, normal: 59-104 µmol/L) (F=10.385, P=0.000). Conclusion: Preliminary results show that taking tamsulosin hydrochloride might lead to renal damage in old patients with benign prostatic hyperplasia. Safety is the premise, and the right medicine should be chosen for different side effects in order to protect the safety of patient.

[Recent progress in MRI-ultrasound fusion for guidance of targeted prostate biopsy].

Prostate cancer is currently diagnosed by prostate biopsy performed by the transrectal ultrasound-guided technique. However, overdetection of clinical insignificant tumours and missed detection of clinical significant tumours have become problematic. MRI of the prostate, particularly if performed with multiparametric imaging, is capable of detecting clinical significant prostate cancer, which has brought the opportunity to use those images as targets for needle biopsy. Three methods of fusing MRI for targeted biopsy have been recently described: MRI-ultrasound fusion, MRI-MRI fusion ('in-bore' biopsy) and cognitive fusion. Fusion of MRI with ultrasound allows urologists to progress from blind, systematic biopsies to biopsies, which are mapped, targeted and tracked. In the future, MRI-ultrasound fusion for lesion targeting is likely to result in fewer and more accurate prostate biopsies than the present use of systematic biopsies with ultrasound guidance alone.